<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="152">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002805</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome</studytitle>
    <scientifictitle>Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CCG-2951</secondaryid>
    <secondaryid>2951</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - cladribine
Treatment: drugs - cytarabine
Treatment: drugs - etoposide
Treatment: drugs - methotrexate
Treatment: drugs - mitoxantrone hydrochloride
Treatment: drugs - therapeutic hydrocortisone
Treatment: surgery - allogeneic bone marrow transplantation
Treatment: surgery - autologous bone marrow transplantation
Treatment: surgery - peripheral blood stem cell transplantation
Treatment: other - low-LET cobalt-60 gamma ray therapy
Treatment: other - low-LET electron therapy
Treatment: other - low-LET photon therapy

Experimental: Treatment - Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.


Other interventions: filgrastim


Treatment: drugs: cladribine


Treatment: drugs: cytarabine


Treatment: drugs: etoposide


Treatment: drugs: methotrexate


Treatment: drugs: mitoxantrone hydrochloride


Treatment: drugs: therapeutic hydrocortisone


Treatment: surgery: allogeneic bone marrow transplantation


Treatment: surgery: autologous bone marrow transplantation


Treatment: surgery: peripheral blood stem cell transplantation


Treatment: other: low-LET cobalt-60 gamma ray therapy


Treatment: other: low-LET electron therapy


Treatment: other: low-LET photon therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Estimate second remission rate and survival rate</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the mortality of the start of VP-16/Ara-C intensification</outcome>
      <timepoint>45 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare outcomes by the ethnicity and gender - Compare outcomes by the ethnicity (and gender) in study CCG-2951, and will control for ethnicity in multivariate models comparing the treatment arms</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Acute myeloid leukemia (AML) or myelodysplastic syndrome in one of
        the following categories: In first relapse Failed to achieve initial complete remission
        Newly diagnosed secondary AML eligible Required bone marrow status: Greater than 25% blasts
        (M3) OR Persistent abnormal clone on cytogenetics and 5-25% blasts (M2) No Fanconi's anemia

        PATIENT CHARACTERISTICS: Age: Under 22 Performance status: Not specified Hematopoietic: See
        Disease Characteristics Hepatic: Bilirubin no greater than 1.5 times normal AST or ALT less
        than 4.0 times normal Renal: Creatinine no greater than 1.5 times normal OR Creatinine
        clearance or GFR greater than 70 mL/min per 1.73 square meters or GFR in equivalent
        institutional normal range Cardiovascular: Shortening fraction greater than 27% by
        echocardiogram or in institutional normal range OR Ejection fraction greater than 47% by
        radionuclide angiogram

        PRIOR CONCURRENT THERAPY: No more than 1 prior treatment No prior salvage therapy No prior
        mitoxantrone</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/1997</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>115</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did
      not achieve first remission.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002805</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert J. Wells, MD</name>
      <address>Children's Hospital Medical Center, Cincinnati</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>